Jim Chomas Named President of Blue Room Investing

DENVER--(BUSINESS WIRE)-- Private investment company Blue Room Investing (“Blue Room”) announced the appointment of Jim Chomas to President today. Based in Blue Room’s Denver headquarters, Chomas will bring his decades of insight, experience and leadership to both Blue Room’s impact investments as well as their investment fund.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220118005907/en/

(Graphic: Business Wire)

Blue Room Founder & Director Minyoung Sohn states, “Since our founding in 2020, we have invested our energy and resources into building our people, establishing our culture and refining our business priorities. Jim makes our company stronger and we seek to leverage his experience leading early stage companies from concept to commercialization. He is an excellent personality fit and strategic fit for Blue Room.”

Emily Philpott, Chief Operating Officer & Chief Creative Officer of Blue Room, adds, “We are so excited to be at the point in our trajectory where we can bring Jim Chomas on board. He has a brilliant ability to understand our value proposition and culture as he helps us grow the business and launch Fund One.”

Chomas shares, “I am excited to transition my experience to Blue Room to help drive progress across the impact companies and investments by applying my creative problem solving and deep experience to high social yield projects in grain, housing and art.”

Prior to joining Blue Room, Chomas served in CEO roles at multiple medical device and wellness companies, starting with Surefire Medical which he founded in 2009 and where he oversaw tremendous growth, from initial invention to sales in hundreds of cancer centers in both the US and Internationally. Before Surefire, Chomas led innovations at Cabochon (acquired by Ulthera, Inc.) and Siemens Healthcare. He is a prolific inventor, with over fifty US and international patents, and many of his medical device inventions remain in clinical use today. Chomas currently serves on the board of KromaTiD, and is a member of the Colorado Bioscience Association, Economic Club of Colorado, and has served on multiple board roles in venture-backed start-ups. Chomas earned a bachelor’s degree from Duke University with a dual major in electrical and biomedical engineering, and a Ph.D. from the University of Virginia in biomedical engineering.

Blue Room was founded by Minyoung Sohn, Emily Philpott and Nina Sohn in 2020 on the principles of investment and impact, dedicating 10% of their revenues to social impact projects at no additional cost to investors. They continue to directly support regenerative agriculture, affordable housing, democratization of education and the arts. Blue Room’s debut Fund One launched in October 2021.

For more information about Blue Room, visit:
blueroominvesting.com
https://www.instagram.com/blueroominvesting/
https://twitter.com/__BLUE__ROOM__
https://vimeo.com/blueroominvesting

View source version on businesswire.com: https://www.businesswire.com/news/home/20220118005907/en/

Media Contacts:
Cole Wilson
[email protected]

Stefanie Nester
[email protected]

Investor Contact:
Emily Philpott
COO & CCO
[email protected]

Source: Blue Room Investing

You May Also Be Interested In

• Industry-Leading JMG Joins Keller Williams
• Noble Capital Markets Initiates Equity Research Coverage on VivoPower
• COSRX Shines at VidCon 2026 With Blue Peptide-Themed Skincare Experience